Ildong Pharmaceutical Future Growth
Future criteria checks 4/6
Ildong Pharmaceutical is forecast to grow earnings and revenue by 75.1% and 6.9% per annum respectively. EPS is expected to grow by 75.6% per annum. Return on equity is forecast to be 22.6% in 3 years.
Key information
75.1%
Earnings growth rate
75.6%
EPS growth rate
Pharmaceuticals earnings growth | 35.9% |
Revenue growth rate | 6.9% |
Future return on equity | 22.6% |
Analyst coverage | Low |
Last updated | 10 May 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 726,000 | 60,000 | 69,000 | 84,000 | 1 |
12/31/2025 | 685,500 | 53,800 | 65,000 | 80,000 | 1 |
12/31/2024 | 626,000 | 38,800 | 50,000 | 65,000 | 1 |
3/31/2024 | 605,800 | -69,347 | -44,348 | -26,896 | N/A |
12/31/2023 | 600,758 | -78,928 | -51,785 | -36,615 | N/A |
9/30/2023 | 601,608 | -134,294 | -86,582 | -68,391 | N/A |
6/30/2023 | 615,710 | -105,042 | -78,573 | -62,172 | N/A |
3/31/2023 | 624,122 | -30,654 | -71,129 | -55,437 | N/A |
12/31/2022 | 637,714 | -141,585 | -71,814 | -53,541 | N/A |
9/30/2022 | 628,484 | -181,371 | -63,675 | -48,202 | N/A |
6/30/2022 | 607,365 | -169,297 | -40,716 | -22,525 | N/A |
3/31/2022 | 586,512 | -208,169 | -26,449 | -6,328 | N/A |
12/31/2021 | 560,132 | -99,705 | -30,867 | -11,366 | N/A |
9/30/2021 | 556,191 | -24,892 | -15,450 | 4,822 | N/A |
6/30/2021 | 560,494 | -19,289 | -8,956 | 7,132 | N/A |
3/31/2021 | 556,360 | -24,652 | -17,467 | -2,102 | N/A |
12/31/2020 | 561,845 | -13,019 | 2,442 | 19,366 | N/A |
9/30/2020 | 544,875 | -14,649 | -1,185 | 16,476 | N/A |
6/30/2020 | 527,837 | -20,373 | -4,549 | 15,155 | N/A |
3/31/2020 | 526,985 | -20,455 | 9,773 | 28,138 | N/A |
12/31/2019 | 517,468 | -13,444 | 24,043 | 41,366 | N/A |
9/30/2019 | 526,601 | 4,344 | 46,440 | 63,654 | N/A |
6/30/2019 | 525,063 | 12,296 | 53,319 | 70,151 | N/A |
3/31/2019 | 514,105 | 12,308 | 54,218 | 72,736 | N/A |
12/31/2018 | 503,907 | 12,721 | 46,257 | 66,647 | N/A |
9/30/2018 | 486,540 | 19,747 | 16,412 | 56,675 | N/A |
6/30/2018 | 486,262 | 24,534 | 17,341 | 60,184 | N/A |
3/31/2018 | 473,014 | 23,666 | 19,862 | 65,564 | N/A |
12/31/2017 | 460,651 | 19,841 | N/A | 73,724 | N/A |
12/31/2016 | 483,225 | 30,189 | N/A | 45,977 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A249420 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: A249420 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: A249420 is expected to become profitable in the next 3 years.
Revenue vs Market: A249420's revenue (6.9% per year) is forecast to grow slower than the KR market (10% per year).
High Growth Revenue: A249420's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A249420's Return on Equity is forecast to be high in 3 years time (22.6%)